Predictors of damage and survival in patients with Wegener's granulomatosis: Analysis of 50 patients

Journal of Rheumatology

Volumn 37, Issue 2, 2010, Pages 374-378

  Kamali, Sevil ^a   Erer, Burak ^a   Artim Esen, Bahar ^a   Gul, Ahmet ^a   Ocal, Lale ^a   Konice, Meral ^a   Aral, Orhan ^a   Inanc, Murat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Vasculitis; Vasculitis damage index; Wegener's granulomatosis

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUBERCULOSTATIC AGENT; VITAMIN D;

ADOLESCENT; ADULT; AGED; AMENORRHEA; ARTICLE; ASTHMA; AVASCULAR NECROSIS; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COHORT ANALYSIS; DEATH; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE COURSE; DRUG MEGADOSE; DRUG PULSE THERAPY; DYSPNEA; EARLY MENOPAUSE; EXOPHTHALMOS; FEMALE; FOLLOW UP; HEARING LOSS; HEMORRHAGIC CYSTITIS; HUMAN; KIDNEY FAILURE; LUNG FIBROSIS; LUNG TUBERCULOSIS; MALE; MONONEUROPATHY MULTIPLEX; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; OSTEOPOROSIS; POLYNEUROPATHY; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RELAPSE; REMISSION; SENESCENCE; SENSITIVITY AND SPECIFICITY; SEPSIS; SUBGLOTTIC STENOSIS; SURVIVAL RATE; SURVIVOR; TREATMENT DURATION; TURKEY (REPUBLIC); WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CYCLOPHOSPHAMIDE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 76649132632     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090387     Document Type: Article

References (28)

1. Stone JH, Hoffman GS. Wegener's granulomatosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia: Elsevier Limited; 2008:1533-44.
2. Seo P, Luqmani RA, Flossman O, Hellmich B, Herlyn K, Hoffman GS, et al. The future of damage assessment in vasculitis. J Rheumatol 2007;34:1357-71
3. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and early validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
4. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology 2002;41:572-81.
5. Kamali S, Inanc M, Gul A, Ocal L, Polat NG, Kilicaslan I, et al. Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients. Rheumatol Int 2005;26:16-20.
6. Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al; WGET Research Group. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78.
7. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis: Arthritis Rheum 1990;33:1101-7.
8. http://www.vasculitis.org/scoring/BVAS%202003.pdf
9. Exley AR, Carruthers DM, Luqmani RA, Kitas GD, Gordon C, Janssen BA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM 1997;90:391-9.
10. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995;101 Suppl 1:29-34.
11. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis. Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85.
12. Jayne D, Rasmussen N, Andrassy K, Bacon P, Cohen Tervaert JW, Dadoniene J, et al. For the European vasculitis study group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
13. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med1992;15;116:488-98.
14. Tervaert JW, Huitema MG, Hene RJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based antineutrophil antibody titre. Lancet 1990;336:709-11.
15. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis QJM 1995;88:127-33.
16. Westman KW, Bygren PG, Olsson H, Rantsam J, Weslander J. Relapse rate, renal survival and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-52.
17. Gottenberg J-E, Mahr A, Pagnoux C, Cohen P, Mouthon L, Guillevin L, for the French Vasculitis Study Group (FVSG). Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement. Presse Med 2007;36:771-8.
18. Mekhail TM, Hoffmann GS. Longterm outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis. J Rheumatol 2000;27:1237-40
19. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibodies-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990;113:656-63.
20. Hogan S, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23-32.
21. Jayne DR. Evidence based treatment of systemic vasculitis. Rheumatology 2000;39:585-95.
22. Boumpas DT, Austin HA, Vaughan EM, et al. Risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
23. Reinhold-Keller E, Beuge N, Katza U, de Groot K, Rudert H, Nolle B et al. An intradisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.
24. Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008;35:100-5.
25. Anderson G, Coles E, Crane M. et al. Wegener's granuloma: A series of 265 British cases seen between 1975 and 1985. A report by a subcommittee of British Thoracic Society Research Committee. QJM 1992;83;427-38.
26. Boki KA, Dafni U, Karpouzas GA, Papasteriades C, Drosos A, Moutsopoulos HM. Necrotizing vasculitis in Greece. Clinical, immunological and immunogenetic aspects. A study of 66 patients. Br J Rheumatol 1997;36:1059-66.
27. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's granulomatosis classification criteria cohort. Am J Med 1996;101:129-34.
28. Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum. 2004;51:83-91.